A Phase 1 interventional study of AMG 706 and Panitumumab in Lung Cancer, Pancreatic Cancer and Esophageal Cancer, sponsored by Amgen. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-03-20.
Sponsored by Amgen · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 94 studies testing gemcitabine in Lung Neoplasms — 2 open to participants now, 3 under way, 1 of them phase 3. Gemcitabine · Lung Neoplasms.
Among the 94 studies testing gemcitabine in Lung Neoplasms, this one is the 43rd largest by enrollment of the 78 interventional ones that give a count, is one of 8 that started in 2004, is one of 9 in phase 1, and was the 39th registered.
5,424 studies on the registry are indexed under Lung Neoplasms; 1,345 are open to participants now.
Browse Lung Neoplasms studies →2 of the 94 studies testing gemcitabine in Lung Neoplasms are open now, in 1 country. Recruiting first, the newest first:
Fox Chase Cancer Center · Sites in United States
Ages 18+
Henan Cancer Hospital
Ages 18–70
By country, each count listing its studies:
Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →
Of the 995 Lung Neoplasms studies recruiting now, 682 (69%) set no upper age limit and 142 (14%) stop at 75 or younger; 45 take children under 18; 142 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
94 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 66 · Phase 3 19
First in 1997; this study’s year is marked. 8 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41 is below the median of 60 across 3,657 interventional studies indexed under Lung Neoplasms.
Median enrollment 47 across the 78 interventional studies. Of the 71 that completed or were terminated, 24 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 94 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
22 studies in Lung Neoplasms by Amgen: 1 open now, 2 under way, 1 of them phase 3. Of 15 finished, 8 (53%) have results posted.
Among the 22 studies in Lung Neoplasms by Amgen, this one is the 11th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2004, is one of 4 in phase 1, and was the 8th registered.
Amgen’s Lung Neoplasms studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 94 studies testing gemcitabine in Lung Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 22 in Lung Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to characterize the safety and tolerability of AMG 706 plus panitumumab when administered with gemcitabine and cisplatin chemotherapy. This is a Phase 1b clinical study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For complete inclusion and exclusion, please refer to the investigator.
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Panitumumab 9 mg/kg intravenously on Day 1 + gemcitabine (gem) 1250 mg/m\^2 on Day 1 and Day 8, and cisplatin (cis) 75 mg/m\^2 on Day 1 of each 3-week cycle.
Biological: Panitumumab · Drug: Gemcitabine · Drug: Cisplatin
AMG 706 50 mg administered orally once daily (QD) + panitumumab 9 mg/kg intravenously on Day 1 + gemcitabine (gem) 1250 mg/m\^2 on Day 1 and Day 8, and cisplatin (cis) 75 mg/m\^2 on Day 1 of each 3-week cycle.
Drug: AMG 706 · Biological: Panitumumab · Drug: Gemcitabine · Drug: Cisplatin
AMG 706 75 mg administered orally once daily (QD) + panitumumab 9 mg/kg intravenously on Day 1 + gemcitabine (gem) 1250 mg/m\^2 on Day 1 and Day 8, and cisplatin (cis) 75 mg/m\^2 on Day 1 of each 3-week cycle.
Drug: AMG 706 · Biological: Panitumumab · Drug: Gemcitabine · Drug: Cisplatin
AMG 706 100 mg administered orally once daily (QD) + panitumumab 9 mg/kg intravenously on Day 1 + gemcitabine (gem) 1250 mg/m\^2 on Day 1 and Day 8, and cisplatin (cis) 75 mg/m\^2 on Day 1 of each 3-week cycle.
Drug: AMG 706 · Biological: Panitumumab · Drug: Gemcitabine · Drug: Cisplatin
AMG 706 125 mg administered orally once daily (QD) + panitumumab 9 mg/kg intravenously on Day 1 + gemcitabine (gem) 1250 mg/m\^2 on Day 1 and Day 8, and cisplatin (cis) 75 mg/m\^2 on Day 1 of each 3-week cycle.
Drug: AMG 706 · Biological: Panitumumab · Drug: Gemcitabine · Drug: Cisplatin
AMG 706 75 mg administered orally twice daily (BID) + panitumumab 9 mg/kg intravenously on Day 1 + gemcitabine (gem) 1250 mg/m\^2 on Day 1 and Day 8, and cisplatin (cis) 75 mg/m\^2 on Day 1 of each 3-week cycle.
Drug: AMG 706 · Biological: Panitumumab · Drug: Gemcitabine · Drug: Cisplatin
AMG 706 will be provided as 25-mg and 100-mg tablets and will be continuously self-administered orally once or twice daily based on cohort assignment starting on day 1 of Cycle 1.
Panitumumab will be administered by intravenous (IV) infusion at a dose of 9 mg/kg on Day 1 of each 3-week cycle.
Also known as: Vectibix
Gemcitabine will be administered intravenously on Day 1 and Day 8 of each 21-day cycle at a dose of 1250 mg/m\^2.
Also known as: Gemzar
Cisplatin will be administered intravenously on Day 1 of each 3-week cycle at a dose of 75 mg/m\^2.
Also known as: cisplatinum, cis-diamminedichloridoplatinum(II) (CDDP)
Participant Incidence of Adverse Events
The number of participants who experienced at least one treatment-emergent adverse event. Additional details regarding specfic adverse events are provided in the Adverse Event section of this posting.
Time frame: From the first dose of any study treatment until 30 days after the last dose of study treatment, up to a maximum of 509 days.
Number of Participants With an Objective Tumor Response
The number of participants with a confirmed objective tumor response, defined as a complete response (CR) or partial response (PR) throughout based on modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Any CR or PR was to be confirmed 4 to 6 weeks after the initial CR or PR.
Time frame: From enrollment until date of last follow-up visit. The median follow-up time was 24 weeks, with a range of 3 to 73 weeks.
Tmax
Time after dosing when maximum plasma concentration was observed for AMG 706
Time frame: Day 1, pre-dose and at 1, 3, 6,12 (BID cohort only) and 24 hours post-dose.
Cmax
The maximum observed plasma concentration after AMG 706 dosing
Time frame: Day 1, pre-dose and at 1, 3, 6,12 (BID cohort only) and 24 hours post-dose.
AUC0-24
Area under the plasma concentration-time curve from time 0 to 24 hours postdose (AUC0-24) with AMG 706. AUC0-24 was estimated using the linear/log trapezoidal method. For the BID cohort, AUC0 24 was estimated as 2 times the AUC from time 0 to 12 hours post the first daily dose (AUC0-12) using the linear/log trapezoidal method.
Time frame: Day 1, pre-dose and at 1, 3, 6,12 (BID cohort only) and 24 hours post-dose.
AUC0-inf
Area under the concentration-time curve from time 0 to infinite time (AUC0-inf) postdose with AMG 706. AUC0-inf was estimated using the linear/log trapezoidal method. AUC0-inf was not calculated for the BID cohort.
Time frame: Day 1, pre-dose and at 1, 3, 6,12 (BID cohort only) and 24 hours post-dose.
Participants were enrolled from 2 December 2004 through 7 March 2007. This study was designed with two parts. However, Part 2 was not conducted due to safety issues found in Part 1. Thus Part 1 is referenced as the overall study here.
| Milestone | Panitumumab + Gem/Cis | 50 mg QD AMG 706 + Panitumumab + Gem/Cis | 75 mg QD AMG 706 + Panitumumab + Gem/Cis | 100 mg QD AMG 706 + Panitumumab + Gem/Cis | 125 mg QD AMG 706 + Panitumumab + Gem/Cis | 75 mg BID AMG 706 + Panitumumab + Gem/Cis |
|---|---|---|---|---|---|---|
| Started | 8 | 8 | 6 | 6 | 11 | 2 |
| Completed | 6 | 7 | 5 | 5 | 6 | 2 |
| Not completed | 2 | 1 | 1 | 1 | 5 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 1 | 0 | 0 | 3 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 1 | 0 | 1 | 0 |
The number of participants with a confirmed objective tumor response, defined as a complete response (CR) or partial response (PR) throughout based on modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Any CR or PR was to be confirmed 4 to 6 weeks after the initial CR or PR.
| participants | Panitumumab + Gem/Cis | 50 mg QD AMG 706 + Panitumumab + Gem/Cis | 75 mg QD AMG 706 + Panitumumab + Gem/Cis | 100 mg QD AMG 706 + Panitumumab + Gem/Cis | 125 mg QD AMG 706 + Panitumumab + Gem/Cis | 75 mg BID AMG 706 + Panitumumab + Gem/Cis |
|---|---|---|---|---|---|---|
| Number of Participants With an Objective Tumor Response | 2 | 0 | 1 | 4 | 2 | 1 |
Time after dosing when maximum plasma concentration was observed for AMG 706
| hours | 50 mg QD AMG 706 + Panitumumab + Gem/Cis | 75 mg QD AMG 706 + Panitumumab + Gem/Cis | 100 mg QD AMG 706 + Panitumumab + Gem/Cis | 125 mg QD AMG 706 + Panitumumab + Gem/Cis | 75 mg BID AMG 706 + Panitumumab + Gem/Cis |
|---|---|---|---|---|---|
| Tmax | 1.00 (1.00 to 3.00) | 1.00 (1.00 to 3.00) | 1.38 (1.00 to 3.00) | 1.00 (1.00 to 3.00) | 1.00 (1.00 to 1.00) |
The maximum observed plasma concentration after AMG 706 dosing
| ng/mL | 50 mg QD AMG 706 + Panitumumab + Gem/Cis | 75 mg QD AMG 706 + Panitumumab + Gem/Cis | 100 mg QD AMG 706 + Panitumumab + Gem/Cis | 125 mg QD AMG 706 + Panitumumab + Gem/Cis | 75 mg BID AMG 706 + Panitumumab + Gem/Cis |
|---|---|---|---|---|---|
| Cmax | 152 ± 78 | 186 ± 92 | 278 ± 90 | 458 ± 208 | 268 ± NA |
Area under the plasma concentration-time curve from time 0 to 24 hours postdose (AUC0-24) with AMG 706. AUC0-24 was estimated using the linear/log trapezoidal method. For the BID cohort, AUC0 24 was estimated as 2 times the AUC from time 0 to 12 hours post the first daily dose (AUC0-12) using the linear/log trapezoidal method.
| μg*hr/mL | 50 mg QD AMG 706 + Panitumumab + Gem/Cis | 75 mg QD AMG 706 + Panitumumab + Gem/Cis | 100 mg QD AMG 706 + Panitumumab + Gem/Cis | 125 mg QD AMG 706 + Panitumumab + Gem/Cis | 75 mg BID AMG 706 + Panitumumab + Gem/Cis |
|---|---|---|---|---|---|
| AUC0-24 | 1.03 ± 0.50 | 1.31 ± 0.51 | 2.38 ± NA | 2.82 ± 1.02 | 2.54 ± NA |
Area under the concentration-time curve from time 0 to infinite time (AUC0-inf) postdose with AMG 706. AUC0-inf was estimated using the linear/log trapezoidal method. AUC0-inf was not calculated for the BID cohort.
| μg*hr/mL | 50 mg QD AMG 706 + Panitumumab + Gem/Cis | 75 mg QD AMG 706 + Panitumumab + Gem/Cis | 100 mg QD AMG 706 + Panitumumab + Gem/Cis | 125 mg QD AMG 706 + Panitumumab + Gem/Cis | 75 mg BID AMG 706 + Panitumumab + Gem/Cis |
|---|---|---|---|---|---|
| AUC0-inf | 1.12 ± 0.52 | 1.64 ± 0.48 | 2.59 ± NA | 3.05 ± 1.34 | — |
The number of participants who experienced at least one treatment-emergent adverse event. Additional details regarding specfic adverse events are provided in the Adverse Event section of this posting.
| Participants | Panitumumab + Gem/Cis | 50 mg QD AMG 706 + Panitumumab + Gem/Cis | 75 mg QD AMG 706 + Panitumumab + Gem/Cis | 100 mg QD AMG 706 + Panitumumab + Gem/Cis | 125 mg QD AMG 706 + Panitumumab + Gem/Cis | 75 mg BID AMG 706 + Panitumumab + Gem/Cis |
|---|---|---|---|---|---|---|
| Participant Incidence of Adverse Events | 8 | 8 | 6 | 6 | 11 | 2 |
Collected over From the first dose of any study treatment until 30 days after the last dose of study treatment, up to a maximum of 509 days.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Panitumumab + Gem/Cis | — | 2/8 (25%) | 8/8 (100%) |
| 50 mg QD AMG 706 + Panitumumab + Gem/Cis | — | 4/8 (50%) | 8/8 (100%) |
| 75 mg QD AMG 706 + Panitumumab + Gem/Cis | — | 3/6 (50%) | 6/6 (100%) |
| 100 mg QD AMG 706 + Panitumumab + Gem/Cis | — | 4/6 (66.7%) | 6/6 (100%) |
| 125 mg QD AMG 706 + Panitumumab + Gem/CisEdit | — | 9/11 (81.8%) | 11/11 (100%) |
| 75 mg BID AMG 706 + Panitumumab + Gem/CisEdit | — | 1/2 (50%) | 2/2 (100%) |
| Event | Panitumumab + Gem/Cis | 50 mg QD AMG 706 + Panitumumab + Gem/Cis | 75 mg QD AMG 706 + Panitumumab + Gem/Cis | 100 mg QD AMG 706 + Panitumumab + Gem/Cis | 125 mg QD AMG 706 + Panitumumab + Gem/CisEdit | 75 mg BID AMG 706 + Panitumumab + Gem/CisEdit |
|---|---|---|---|---|---|---|
| Arterial thrombosisVascular disorders | 0/8 | 0/8 | 0/6 | 0/6 | 1/11 | 1/2 |
| DehydrationMetabolism and nutrition disorders | 1/8 | 1/8 | 0/6 | 0/6 | 3/11 | 0/2 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/8 | 1/8 | 1/6 | 1/6 | 3/11 | 0/2 |
| Deep vein thrombosisVascular disorders | 0/8 | 2/8 | 0/6 | 1/6 | 2/11 | 0/2 |
| DiarrhoeaGastrointestinal disorders | 0/8 | 0/8 | 0/6 | 0/6 | 2/11 | 0/2 |
| AnaemiaBlood and lymphatic system disorders | 0/8 | 1/8 | 0/6 | 1/6 | 0/11 | 0/2 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/8 | 0/8 | 0/6 | 1/6 | 0/11 | 0/2 |
| Angina pectorisCardiac disorders | 0/8 | 0/8 | 1/6 | 0/6 | 0/11 | 0/2 |
| CardiomyopathyCardiac disorders | 0/8 | 0/8 | 0/6 | 1/6 | 0/11 | 0/2 |
| Oesophageal perforationGastrointestinal disorders | 0/8 | 0/8 | 1/6 | 0/6 | 0/11 | 0/2 |
| Event | Panitumumab + Gem/Cis | 50 mg QD AMG 706 + Panitumumab + Gem/Cis | 75 mg QD AMG 706 + Panitumumab + Gem/Cis | 100 mg QD AMG 706 + Panitumumab + Gem/Cis | 125 mg QD AMG 706 + Panitumumab + Gem/CisEdit | 75 mg BID AMG 706 + Panitumumab + Gem/CisEdit |
|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 6/8 | 6/8 | 5/6 | 6/6 | 10/11 | 1/2 |
| FatigueGeneral disorders | 5/8 | 7/8 | 3/6 | 4/6 | 10/11 | 2/2 |
| HypomagnesaemiaMetabolism and nutrition disorders | 2/8 | 3/8 | 3/6 | 3/6 | 6/11 | 2/2 |
| ErythemaSkin and subcutaneous tissue disorders | 5/8 | 5/8 | 6/6 | 5/6 | 3/11 | 1/2 |
| PruritusSkin and subcutaneous tissue disorders | 5/8 | 2/8 | 5/6 | 5/6 | 0/11 | 2/2 |
| RashSkin and subcutaneous tissue disorders | 6/8 | 5/8 | 2/6 | 4/6 | 3/11 | 2/2 |
| AnaemiaBlood and lymphatic system disorders | 6/8 | 5/8 | 2/6 | 5/6 | 4/11 | 1/2 |
| NeutropeniaBlood and lymphatic system disorders | 4/8 | 5/8 | 4/6 | 5/6 | 3/11 | 0/2 |
| Mucosal inflammationGeneral disorders | 4/8 | 1/8 | 0/6 | 5/6 | 1/11 | 0/2 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/8 | 1/8 | 5/6 | 1/6 | 2/11 | 0/2 |
| Age, Continuous(years) | Panitumumab + Gem/Cis | 50 mg QD AMG 706 + Panitumumab + Gem/Cis | 75 mg QD AMG 706 + Panitumumab + Gem/Cis | 100 mg QD AMG 706 + Panitumumab + Gem/Cis | 125 mg QD AMG 706 + Panitumumab + Gem/Cis | 75 mg BID AMG 706 + Panitumumab + Gem/Cis | Total |
|---|---|---|---|---|---|---|---|
| Mean | 55.5 ± 12.4 | 60.4 ± 13.8 | 56.0 ± 13.3 | 51.5 ± 13.5 | 61.1 ± 8.3 | 65.0 ± 17.0 | 57.9 ± 12.0 |
| Sex: Female, Male(Participants) | Panitumumab + Gem/Cis | 50 mg QD AMG 706 + Panitumumab + Gem/Cis | 75 mg QD AMG 706 + Panitumumab + Gem/Cis | 100 mg QD AMG 706 + Panitumumab + Gem/Cis | 125 mg QD AMG 706 + Panitumumab + Gem/Cis | 75 mg BID AMG 706 + Panitumumab + Gem/Cis | Total |
|---|---|---|---|---|---|---|---|
| Female | 4 | 3 | 2 | 4 | 5 | 0 | 18 |
| Male | 4 | 5 | 4 | 2 | 6 | 2 | 23 |
| Race/Ethnicity, Customized(Participants) | Panitumumab + Gem/Cis | 50 mg QD AMG 706 + Panitumumab + Gem/Cis | 75 mg QD AMG 706 + Panitumumab + Gem/Cis | 100 mg QD AMG 706 + Panitumumab + Gem/Cis | 125 mg QD AMG 706 + Panitumumab + Gem/Cis | 75 mg BID AMG 706 + Panitumumab + Gem/Cis | Total |
|---|---|---|---|---|---|---|---|
| Black or African American | 1 | 1 | 2 | 0 | 0 | 0 | 4 |
| Hispanic or Latino | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| White or Caucasian | 6 | 7 | 4 | 6 | 11 | 2 | 36 |
No study locations are listed for this record.
The record gives a start of Dec 2004, a primary completion of Jun 2007 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2014, 6 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Panitumumab · Gemcitabine · Cisplatin